A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Over 70% of MS patients in rehab take 5 or more medications, study finds
- New research project to explore how women with MS experience menopause
- MS progression is unpredictable, but I’m learning to adapt
- Lucid-MS moves toward clinical trial in US that will enroll MS patients
- With MS, movement can be one of the greatest teachers